Why One Drug Company Held Back a Better Drug
Drug companies say patents spur innovation. Can they also do [...]
Expert Panel Recommends New Drugs for HIV Prevention
The “grade A” endorsement means that two additional drugs should [...]
How Gilead Profited by Slow-Walking a Promising H.I.V. Therapy
Gilead delayed a new version of a drug, allowing it [...]
When Politics Saves Lives: a Good-News Story
The decision to fund medications to treat H.I.V.-AIDS patients in [...]
Gilead Wins Key Patent Rights Suit Over HIV Prevention Drug PrEP
A jury sided with Gilead Sciences in a dispute over [...]
The Only H.I.V. Vaccine in Advanced Trials Has Failed. What Now?
Janssen Pharmaceuticals ended a global trial after independent experts determined [...]
How Anthony Fauci Quietly Shocked AIDS Activists
An ACT UP veteran remembers the doctor’s AIDS legacy.
Un nuevo tratamiento contra el VIH ha probado ser un éxito. ¿Será accesible en África?
Durante varios años ha existido en Sudáfrica una pastilla que [...]
A New Shot Guards Against H.I.V., but Access for Africans Is Uncertain
An injection every two months rather than a daily pill [...]
McKinsey Guided Companies at the Center of the Opioid Crisis
The consulting firm offered clients “in-depth experience in narcotics,” from [...]